Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06
Asparaginase is an important drug in the treatment of childhood leukemia including in infant (<1 year). The prognosis for infants is bad.
Information about drug metabolism in neonates and infants is scarce as well as the reactions of an immature immune system to foreign proteins. The aims of this study is to describe the metabolism (pharmacokinetics) of asparaginase after administration intramuscularly and to evaluate the formation of antibodies against the drug (enzyme) during treatment in order to optimize the asparaginase treatment in infants in the future.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Post-marketing Surveillance Study of the Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06|
- pharmacokinetics, antibody formation, side effects [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||December 2009|
|Estimated Study Completion Date:||December 2015|
|Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Combination chemotherapy for acute lymphoblastic leukaemia (ALL) usually includes a bacterial L-asparaginase enzyme derived from Escherichia coli or Erwinia species. Several studies have described the pharmacokinetics in children above 1 year of age of asparaginase given intramuscularly as well as intravenously. The development of anti-asparaginase antibodies to these foreign proteins has also been described.
Chemotherapy for infant ALL also includes L-asparaginase. However, the pharmacokinetics of asparaginase and antibody formation in infants is needed to be described to optimize therapy for this group of patients who have a doubtful prognosis.
Background In general the information about drug metabolism in neonates and infants is scarce as well as the reactions of an immature immune system to foreign proteins. Several pharmacokinetic studies have been performed in children above one year of age, but no data is available about pharmacokinetics and antibody formation during treatment with any asparaginase preparation in infants.
Asparaginase is used in the treatment of childhood ALL since it depletes the blood of asparagines, which can be synthesized by normal cells but not by leukemic lymphoblasts. It has been shown that serum activities above 100 IU/l ensure depletion of asparagine in serum and CNS. In many cases even values considerably lower than 100 IU/l will deplete asparagine from the serum1-5.
In the Interfant-06 protocol the doses of asparaginase are adopted from childhood ALL-protocols without scientific foundation. Infants may metabolise asparaginase differently and thus may not achieve amino acid depletion.
Asparaginase is a foreign protein for the human body, so patients may develop antibodies against it, resulting in allergic reactions (probably mediated by IgE-antibodies) or silent antibodies (IgG antibodies, blocking the effect of the enzyme). In the first case treatment most often is stopped and in the second case treatment is insufficient6-7, and thus giving the patient a poorer prognosis in both cases.
In Interfant-06 patients are treated with native E.coli asparaginase for a period followed by PEG-asparaginase later during their treatment. Studies in older children have shown that approximately 1/3 of the patients develop IgG-antibodies against native E.coli after 5-6 doses7. Other studies have shown that IgG-antibodies against native E.coli asparaginase cross-react with PEG-asparaginase, resulting in a faster clearance of the enzyme8. Allergic reactions (any grade) to native E.coli asparaginase are encountered in approximately 30 % of children11-12. There is no knowledge about the frequency of antibody formation during asparaginase therapy in infants.
The study has the purposes:
- to describe the pharmacokinetics of intramuscular native E.coli and PEG-asparaginase in children below 1 year at diagnosis
- to evaluate antibody formation during asparaginase treatment with E.coli followed by PEG-asparaginase in infants
Please refer to this study by its ClinicalTrials.gov identifier: NCT01025804
|Contact: Birgitte K Albertsen, MD||+45 8949 email@example.com|
|Aarhus University Hospital, Department of Pediatrics Skejby Hospital||Recruiting|
|Aarhus, Aarhus N, Denmark, 8200|
|Contact: Birgitte K Albertsen, MD +45 8949 6841 firstname.lastname@example.org|
|Principal Investigator: Birgitte K Albertsen, MD|
|Copenhagen, Denmark, 2100|
|Contact: Birgitte Lausen, MD +45 3545 8177 Birgitte.Lausen@rh.regionh.dk|
|Principal Investigator: Birgitte Lausen, MD|
|Helsinki University Hospital||Recruiting|
|Contact: Kirsi Juhnukainen, MD +358 2 3130000 email@example.com|
|Principal Investigator: Kirsi Juhnukainen, MD|
|University Hospital Reykjavik||Recruiting|
|Contact: Jon Kristinsson, MD firstname.lastname@example.org|
|Principal Investigator: Jon Kristinsson, md|
|Contact: Bem Zeller, MD +47 23069953 email@example.com|
|Principal Investigator: Bem Zeller, MD|
|Contact: Stefan Söderhäll, MD +46 8 51774714 firstname.lastname@example.org|
|Principal Investigator: Stefan Söderhäll, MD|
|Study Chair:||Birgitte K Albertsen, MD|